CoChat
Sign Up
Cited by 140Chronic Kidney Disease and DiabetesAdvanced Glycation End Products researchDialysis and Renal Disease Management

The DOI matches its Crossref record; the references it cites are not checked yet.

Inflammatory Cytokines in Diabetic Kidney Disease: Pathophysiologic and Therapeutic Implications

Open access
Donate-Correa, Javier, Ferri, Carla M., Sánchez-Quintana, Fátima, Pérez-Castro, Atteneri, González-Luis, Ainhoa, Martín-Núñez, Ernesto, Mora-Fernández, Carmen, Navarro-González, Juan F.·2021·Frontiers in Medicine
DOI 10.3389/fmed.2020.628289PMC PMC7862763
Open this paper in CoChat — free accountOpen PDF

Abstract

Diabetic kidney disease (DKD) is the leading cause of end-stage renal disease and a main contributing factor for cardiovascular morbidity and mortality in patients with diabetes mellitus. Strategies employed to delay the progression of this pathology focus on the control of traditional risk factors, such as hyperglycemia, and elevated blood pressure. Although the intimate mechanisms involved in the onset and progression of DKD remain incompletely understood, inflammation is currently recognized as one of the main underlying processes. Untangling the mechanisms involved in the appearing of a harmful inflammatory response in the diabetic patient is crucial for the development of new therapeutic strategies. In this review, we focus on the inflammation-related pathogenic mechanisms involved in DKD and in the therapeutic utility of new anti-inflammatory strategies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fmed.2020.628289

Cites

Statistics

Figures

Figure 1 Inflammatory pathophysiology in diabetic kidney disease. The diabetic milieu drives to the development of inflammation that includes the activation of immune cells and the upregulation of pro-inflammatory cytokines. Activated immune cells migrates and infiltrates the renal tissue locally producing more inflammatory mediators and chemokines that recruit more immune cells into the kidney. Moreover, activated resident renal cells can also produce additional proinflammatory mediators, contributing to sustained inflammation, and the induction of kidney damage. Created with BioRender.com.
Figure 1 Inflammatory pathophysiology in diabetic kidney disease. The diabetic milieu drives to the development of inflammation that includes the activation of immune cells and the upregulation of pro-inflammatory cytokines. Activated immune cells migrates and infiltrates the renal tissue locally producing more inflammatory mediators and chemokines that recruit more immune cells into the kidney. Moreover, activated resident renal cells can also produce additional proinflammatory mediators, contributing to sustained inflammation, and the induction of kidney damage. Created with BioRender.com.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

The citation lists haven’t been fetched yet

References 122 · Cited by 140

Research works printed but not linked: 118

  1. Ritz, 1999, End-stage renal failure in type 2 diabetes: a medical catastrophe of worldwide dimensions, Am J Kidney Dis., 34, 795, 10.1016/S0272-6386(99)70035-1 · DOI
  2. Atkins, 2005, The epidemiology of chronic kidney disease, Kidney Int Suppl., S14, 10.1111/j.1523-1755.2005.09403.x · DOI
  3. Wolf, 2004, New insights into the pathophysiology of diabetic nephropathy: from haemodynamics to molecular pathology, Eur J Clin Invest., 34, 785, 10.1111/j.1365-2362.2004.01429.x · DOI
  4. Wada, 2013, Inflammation and the pathogenesis of diabetic nephropathy, Clin Sci., 124, 139, 10.1042/CS20120198 · DOI
  5. Schmidt, 1999, Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): a cohort study, Lancet., 353, 1649, 10.1016/S0140-6736(99)01046-6 · DOI
  6. Spranger, 2003, Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study, Diabetes., 52, 812, 10.2337/diabetes.52.3.812 · DOI · Paper page
  7. Hasegawa, 1991, Possible role of tumor necrosis factor and interleukin-1 in the development of diabetic nephropathy, Kidney Int., 40, 1007, 10.1038/ki.1991.308 · DOI
  8. Moriwaki, 2003, Elevated levels of interleukin-18 and tumor necrosis factor-alpha in serum of patients with type 2 diabetes mellitus: relationship with diabetic nephropathy, Metabolism., 52, 605, 10.1053/meta.2003.50096 · DOI
  9. Chow, 2004, Macrophages in mouse type 2 diabetic nephropathy: correlation with diabetic state and progressive renal injury, Kidney Int., 65, 116, 10.1111/j.1523-1755.2004.00367.x · DOI
  10. Nguyen, 2006, Macrophage accumulation in human progressive diabetic nephropathy, Nephrology., 11, 226, 10.1111/j.1440-1797.2006.00576.x · DOI
  11. Lim, 2010, Lymphocytes promote albuminuria, but not renal dysfunction or histological damage in a mouse model of diabetic renal injury, Diabetologia., 53, 1772, 10.1007/s00125-010-1757-1 · DOI
  12. Ferenbach, 2007, Inflammatory cells in renal injury and repair, Semin Nephrol., 27, 250, 10.1016/j.semnephrol.2007.02.001 · DOI
  13. Bruno, 2003, Progression to overt nephropathy in type 2 diabetes: the casale monferrato study, Diabetes Care., 26, 2150, 10.2337/diacare.26.7.2150 · DOI
  14. Festa, 2000, Inflammation and microalbuminuria in nondiabetic and type 2 diabetic subjects: the insulin resistance atherosclerosis study, Kidney Int., 58, 1703, 10.1046/j.1523-1755.2000.00331.x · DOI
  15. Suzuki, 1995, In situ hybridization of interleukin 6 in diabetic nephropathy, Diabetes., 44, 1233, 10.2337/diab.44.10.1233 · DOI
  16. Nakamura, 2005, Serum interleukin-18 levels are associated with nephropathy and atherosclerosis in Japanese patients with type 2 diabetes, Diabetes Care., 28, 2890, 10.2337/diacare.28.12.2890 · DOI
  17. Wong, 2007, Aberrant activation profile of cytokines and mitogen-activated protein kinases in type 2 diabetic patients with nephropathy, Clin Exp Immunol., 149, 123, 10.1111/j.1365-2249.2007.03389.x · DOI
  18. Okamura, 1995, Cloning of a new cytokine that induces IFN-gamma production by T cells, Nature., 378, 88, 10.1038/378088a0 · DOI
  19. Schwarz, 2002, IFNgamma induces functional chemokine receptor expression in human mesangial cells, Clin Exp Immunol., 128, 285, 10.1046/j.1365-2249.2002.01829.x · DOI
  20. Stuyt, 2003, Selective regulation of intercellular adhesion molecule-1 expression by interleukin-18 and interleukin-12 on human monocytes, Immunology., 110, 329, 10.1046/j.1365-2567.2003.01747.x · DOI
  21. Mariño, 2003, Differential effect of IL-18 on endothelial cell apoptosis mediated by TNF-alpha and Fas (CD95), Cytokine., 22, 142, 10.1016/S1043-4666(03)00150-9 · DOI
  22. Fantuzzi, 1999, IL-12-induced IFN-gamma is dependent on caspase-1 processing of the IL-18 precursor, J Clin Invest., 104, 761, 10.1172/JCI7501 · DOI
  23. Miyauchi, 2009, Upregulated IL-18 expression in type 2 diabetic subjects with nephropathy: TGF-beta1 enhanced IL-18 expression in human renal proximal tubular epithelial cells, Diabetes Res Clin Pract., 83, 190, 10.1016/j.diabres.2008.11.018 · DOI
  24. Chen, 2017, Serum TNF-α concentrations in type 2 diabetes mellitus patients and diabetic nephropathy patients: a systematic review and meta-analysis, Immunol Lett., 186, 52, 10.1016/j.imlet.2017.04.003 · DOI
  25. Beneficial effect of phosphodiesterase-5 inhibitor in experimental inflammatory bowel disease; molecular evidence for involvement of oxidative stress2818 KhoshakhlaghP Bahrololoumi-ShapourabadiM MohammadiradA Ashtaral-NakhaiL MinaieB AbdollahiM 10.1080/1537651060100376920020951Toxicol Mech Methods.172007 · DOI
  26. Sugimoto, 1999, Advanced glycation end products-cytokine-nitric oxide sequence pathway in the development of diabetic nephropathy: aminoguanidine ameliorates the overexpression of tumour necrosis factor-alpha and inducible nitric oxide synthase in diabetic rat glomeruli, Diabetologia., 42, 878, 10.1007/s001250051241 · DOI
  27. Jevnikar, 1991, Stimulated kidney tubular epithelial cells express membrane associated and secreted TNF alpha, Kidney Int., 40, 203, 10.1038/ki.1991.201 · DOI
  28. Navarro, 2006, Urinary tumour necrosis factor-alpha excretion independently correlates with clinical markers of glomerular and tubulointerstitial injury in type 2 diabetic patients, Nephrol Dial Transplant., 21, 3428, 10.1093/ndt/gfl469 · DOI
  29. Navarro, 2006, Renal pro-inflammatory cytokine gene expression in diabetic nephropathy: effect of angiotensin-converting enzyme inhibition and pentoxifylline administration, Am J Nephrol., 26, 562, 10.1159/000098004 · DOI
  30. Navarro, 2005, Tumor necrosis factor-alpha gene expression in diabetic nephropathy: relationship with urinary albumin excretion and effect of angiotensin-converting enzyme inhibition, Kidney Int Suppl., 99, S98, 10.1111/j.1523-1755.2005.09918.x · DOI
  31. DiPetrillo, 2004, Pentoxifylline ameliorates renal tumor necrosis factor expression, sodium retention, and renal hypertrophy in diabetic rats, Am J Nephrol., 24, 352, 10.1159/000079121 · DOI
  32. Sassy-Prigent, 2000, Early glomerular macrophage recruitment in streptozotocin-induced diabetic rats, Diabetes., 49, 466, 10.2337/diabetes.49.3.466 · DOI
  33. Brady, 1994, Leukocyte adhesion molecules and kidney diseases, Kidney Int., 45, 1285, 10.1038/ki.1994.169 · DOI
  34. Park, 2000, High glucose-induced intercellular adhesion molecule-1 (ICAM-1) expression through an osmotic effect in rat mesangial cells is PKC-NF-kappa B-dependent, Diabetologia, 43, 1544, 10.1007/s001250051567 · DOI
  35. Pfeilschifter, 1989, Interleukin 1 and tumor necrosis factor synergistically stimulate prostaglandin synthesis and phospholipase A2 release from rat renal mesangial cells, Biochem Biophys Res Commun., 159, 385, 10.1016/0006-291X(89)90003-X · DOI
  36. Pfeilschifter, 1990, Interleukin 1 and tumor necrosis factor potentiate angiotensin II- and calcium ionophore-stimulated prostaglandin E2 synthesis in rat renal mesangial cells, Biochem Biophys Res Commun., 169, 585, 10.1016/0006-291X(90)90371-S · DOI
  37. Jones, 2001, Regulation of renal proximal tubular epithelial cell hyaluronan generation: implications for diabetic nephropathy, Kidney Int., 59, 1739, 10.1046/j.1523-1755.2001.0590051739.x · DOI
  38. Mahadevan, 1995, Increased hyaluronan production in the glomeruli from diabetic rats: a link between glucose-induced prostaglandin production and reduced sulphated proteoglycan, Diabetologia., 38, 298, 10.1007/BF00400634 · DOI
  39. Vasanthakumar, 2015, Serum IL-9, IL-17, and TGF-beta levels in subjects with diabetic kidney disease (CURES-134), Cytokine., 72, 109, 10.1016/j.cyto.2014.10.009 · DOI
  40. Mohamed, 2016, Low-dose IL-17 therapy prevents and reverses diabetic nephropathy, metabolic syndrome, and associated organ fibrosis, J Am Soc Nephrol., 27, 745, 10.1681/ASN.2014111136 · DOI
  41. Zhang, 2016, Increased CD4+CXCR5+T folicular helper cells in diabetic nephropathy, Autoimmunity., 49, 405, 10.1080/08916934.2016.1196677 · DOI
  42. Galvan, 2016, Paradoxical role of IL-17 in progression of diabetic nephropathy, J Am Soc Nephrol, 27, 657, 10.1681/ASN.2015070813 · DOI
  43. Liu, 2011, Cellular and molecular mechanisms of renal fibrosis, Nat Rev Nephrol., 7, 684, 10.1038/nrneph.2011.149 · DOI
  44. Royall, 1989, Tumor necrosis factor and interleukin 1 alpha increase vascular endothelial permeability, Am J Physiol., 257, L399, 10.1152/ajplung.1989.257.6.L399 · DOI
  45. Coleman, 1992, Interleukin-6: an autocrine regulator of mesangial cell growth, Kidney Int., 41, 604, 10.1038/ki.1992.91 · DOI
  46. Nosadini, 2000, Course of renal function in type 2 diabetic patients with abnormalities of albumin excretion rate, Diabetes., 49, 476, 10.2337/diabetes.49.3.476 · DOI
  47. Dalla Vestra, 2005, Acute-phase markers of inflammation and glomerular structure in patients with type 2 diabetes, J Am Soc Nephrol., 16, S78, 10.1681/ASN.2004110961 · DOI
  48. Araki, 2007, Predictive impact of elevated serum level of IL-18 for early renal dysfunction in type 2 diabetes: an observational follow-up study, Diabetologia., 50, 867, 10.1007/s00125-006-0586-8 · DOI
  49. DiPetrillo, 2003, Urinary tumor necrosis factor contributes to sodium retention and renal hypertrophy during diabetes, Am J Physiol Renal Physiol., 284, F113, 10.1152/ajprenal.00026.2002 · DOI
  50. Yu, 1998, Salt induces myocardial and renal fibrosis in normotensive and hypertensive rats, Circulation., 98, 2621, 10.1161/01.CIR.98.23.2621 · DOI
  51. Kalantarinia, 2003, Urinary and renal interstitial concentrations of TNF-alpha increase prior to the rise in albuminuria in diabetic rats, Kidney Int., 64, 1208, 10.1046/j.1523-1755.2003.00237.x · DOI
  52. Ortiz, 1995, Involvement of tumor necrosis factor-alpha in the pathogenesis of experimental and human glomerulonephritis, Adv Nephrol Necker Hosp., 24, 53
  53. Bertani, 1989, Tumor necrosis factor induces glomerular damage in the rabbit, Am J Pathol, 134, 419
  54. Laster, 1988, Tumor necrosis factor can induce both apoptic and necrotic forms of cell lysis, J Immunol., 141, 2629, 10.4049/jimmunol.141.8.2629 · DOI
  55. Boyle, 2003, Tumor necrosis factor-alpha promotes macrophage-induced vascular smooth muscle cell apoptosis by direct and autocrine mechanisms, Arterioscler Thromb Vasc Biol., 23, 1553, 10.1161/01.ATV.0000086961.44581.B7 · DOI · Paper page
  56. Baud, 1988, Tumor necrosis factor stimulates prostaglandin production and cyclic AMP levels in rat cultured mesangial cells, FEBS Lett., 239, 50, 10.1016/0014-5793(88)80543-X · DOI
  57. McCarthy, 1998, TNF-alpha increases albumin permeability of isolated rat glomeruli through the generation of superoxide, J Am Soc Nephrol., 9, 433, 10.1681/ASN.V93433 · DOI
  58. Induction of reactive oxygen species from isolated rat glomeruli by protein kinase C activation and TNF-alpha stimulation, and effects of a phosphodiesterase inhibitor17218 KoikeN TakamuraT KanekoS 10.1016/j.lfs.2007.02.00117346751Life Sci.802007 · DOI
  59. Cortvrindt, 2017, The role of interleukin-17A in the pathogenesis of kidney diseases, Pathology., 49, 247, 10.1016/j.pathol.2017.01.003 · DOI
  60. Ma, 2019, Interleukin 17A promotes diabetic kidney injury, Sci Rep., 9, 2264, 10.1038/s41598-019-38811-4 · DOI
  61. Van Kooten, 1998, Interleukin-17 activates human renal epithelial cells in vitro is expressed during renal allograft rejection, J Am Soc Nephrol., 9, 1526, 10.1681/ASN.V981526 · DOI
  62. Dudas, 2011, Proinflammatory/profibrotic effects of interleukin-17A on human proximal tubule epithelium, Nephron Exp Nephrol., 117, 114, 10.1159/000320177 · DOI
  63. Orejudo, 2019, Interleukin 17A participates in renal inflammation associated to experimental and human hypertension, Front Pharmacol., 10, 1015, 10.3389/fphar.2019.01015 · DOI
  64. Lavoz, 2019, Interleukin-17A blockade reduces albuminuria and kidney injury in an accelerated model of diabetic nephropathy, Kidney Int., 95, 1418, 10.1016/j.kint.2018.12.031 · DOI
  65. Saleh, 2016, Inhibition of interleukin-17A, but not interleukin-17F, signaling lowers blood pressure, and reduces end-organ inflammation in angiotensin ii–induced hypertension, JACC Basic Transl Sci., 1, 606, 10.1016/j.jacbts.2016.07.009 · DOI
  66. Lee, 2004, Interactions between angiotensin II and NF-kappaB-dependent pathways in modulating macrophage infiltration in experimental diabetic nephropathy, J Am Soc Nephrol., 15, 2139, 10.1097/01.ASN.0000135055.61833.A8 · DOI
  67. Sanz, 2010, NF-kappaB in renal inflammation, J Am Soc Nephrol., 21, 1254, 10.1681/ASN.2010020218 · DOI
  68. Wanner, 2016, Empagliflozin and progression of kidney disease in type 2 diabetes, N Engl J Med., 375, 323, 10.1056/NEJMoa1515920 · DOI · Paper page
  69. Matsumura, 2017, Efficacy of additional canagliflozin administration to type 2 diabetes patients receiving insulin therapy: examination of diurnal glycemic patterns using continuous glucose monitoring (CGM), Diabetes Ther., 8, 821, 10.1007/s13300-017-0274-3 · DOI
  70. Garvey, 2018, Effects of canagliflozin versus glimepiride on adipokines and inflammatory biomarkers in type 2 diabetes, Metabolism., 85, 32, 10.1016/j.metabol.2018.02.002 · DOI
  71. Ferrannini, 2010, Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial, Diabetes Care., 33, 2217, 10.2337/dc10-0612 · DOI
  72. Okamoto, 2016, Changes in levels of biomarkers associated with adipocyte function and insulin and glucagon kinetics during treatment with dapagliflozin among obese type 2 diabetes mellitus patients, Drugs R D., 16, 255, 10.1007/s40268-016-0137-9 · DOI
  73. Hattori, 2018, Empagliflozin decreases remnant-like particle cholesterol in type 2 diabetes patients with insulin resistance, J Diabetes Investig., 9, 870, 10.1111/jdi.12781 · DOI
  74. Tobita, 2017, Effects of Dapagliflozin on body composition and liver tests in patients with nonalcoholic steatohepatitis associated with type 2 diabetes mellitus: a prospective, open-label, uncontrolled study, Curr Ther Res Clin Exp., 87, 13, 10.1016/j.curtheres.2017.07.002 · DOI
  75. Soga, 2018, Impact of dapagliflozin on left ventricular diastolic function of patients with type 2 diabetic mellitus with chronic heart failure, Cardiovasc Diabetol., 17, 132, 10.1186/s12933-018-0775-z · DOI
  76. Kim, 2020, SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease, Nat Commun., 11, 2127, 10.1038/s41467-020-15983-6 · DOI
  77. Panchapakesan, 2013, Effects of SGLT2 inhibition in human kidney proximal tubular cells–renoprotection in diabetic nephropathy?, PLoS ONE., 8, e54442, 10.1371/journal.pone.0054442 · DOI
  78. Mancini, 2018, Canagliflozin inhibits interleukin-1β-stimulated cytokine and chemokine secretion in vascular endothelial cells by AMP-activated protein kinase-dependent and -independent mechanisms, Sci Rep., 8, 5276, 10.1038/s41598-018-23420-4 · DOI · Paper page
  79. Ishibashi, 2016, Tofogliflozin, a highly selective inhibitor of SGLT2 blocks proinflammatory and proapoptotic effects of glucose overload on proximal tubular cells partly by suppressing oxidative stress generation, Horm Metab Res., 48, 191, 10.1055/s-0035-1555791 · DOI
  80. Jaikumkao, 2018, Dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, slows the progression of renal complications through the suppression of renal inflammation, endoplasmic reticulum stress and apoptosis in prediabetic rats, Diabetes Obes Metab., 20, 2617, 10.1111/dom.13441 · DOI
  81. Ishibashi, 2016, Tofogliflozin, a selective inhibitor of sodium-glucose cotransporter 2, suppresses renal damage in KKAy/Ta mice, obese and type 2 diabetic animals, Diab Vasc Dis Res., 13, 438, 10.1177/1479164116657304 · DOI
  82. Han, 2017, The beneficial effects of empagliflozin, an SGLT2 inhibitor, on atherosclerosis in ApoE −/− mice fed a western diet, Diabetologia., 60, 364, 10.1007/s00125-016-4158-2 · DOI · Paper page
  83. Vallon, 2014, SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice, Am J Physiol Renal Physiol., 306, F194, 10.1152/ajprenal.00520.2013 · DOI · Paper page
  84. Lin, 2014, Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice, Cardiovasc Diabetol., 13, 148, 10.1186/s12933-014-0148-1 · DOI · Paper page
  85. Terami, 2014, Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db/db mice, PLoS ONE., 9, e100777, 10.1371/journal.pone.0100777 · DOI
  86. Hattori, 2011, Sitagliptin reduces albuminuria in patients with type 2 diabetes, Endocr J., 58, 69, 10.1507/endocrj.K10E-382 · DOI
  87. Sakata, 2013, Efficacy of alogliptin, a dipeptidyl peptidase-4 inhibitor, on glucose parameters, the activity of the advanced glycation end product (AGE) - receptor for AGE (RAGE) axis and albuminuria in Japanese type 2 diabetes, Diabetes Metab Res Rev., 29, 624, 10.1002/dmrr.2437 · DOI
  88. Barbieri, 2013, Decreased carotid atherosclerotic process by control of daily acute glucose fluctuations in diabetic patients treated by DPP-IV inhibitors, Atherosclerosis., 227, 349, 10.1016/j.atherosclerosis.2012.12.018 · DOI
  89. Ferdinand, 2014, Effects of the once-weekly glucagon-like peptide-1 receptor agonist dulaglutide on ambulatory blood pressure and heart rate in patients with type 2 diabetes mellitus, Hypertension., 64, 731, 10.1161/HYPERTENSIONAHA.114.03062 · DOI
  90. Kanasaki, 2018, The role of renal dipeptidyl peptidase-4 in kidney disease: renal effects of dipeptidyl peptidase-4 inhibitors with a focus on linagliptin, Clin Sci, 132, 489, 10.1042/CS20180031 · DOI
  91. Jo, 2018, Anti-Inflammatory Action of Sitagliptin and Linagliptin in Doxorubicin Nephropathy, Kidney Blood Press Res., 43, 987, 10.1159/000490688 · DOI
  92. Kawanami, 2016, Incretin-Based Therapies for Diabetic Complications: Basic Mechanisms and Clinical Evidence, Int J Mol Sci., 17, 1223, 10.3390/ijms17081223 · DOI
  93. Blagosklonnaia, 1982, Effect of trental on indices kidney function in diabetes mellitus, Probl Endokrinol., 28, 3
  94. Aminorroaya, 2005, Comparison of the effect of pentoxifylline and captopril on proteinuria in patients with type 2 diabetes mellitus, Nephron Clin Pract., 99, c73, 10.1159/000083417 · DOI
  95. Rodríguez-Morán, 2005, Pentoxifylline is as effective as captopril in the reduction of microalbuminuria in non-hypertensive type 2 diabetic patients–a randomized, equivalent trial, Clin Nephrol., 64, 91, 10.5414/CNP64091 · DOI
  96. Navarro, 2005, Additive antiproteinuric effect of pentoxifylline in patients with type 2 diabetes under angiotensin II receptor blockade: a short-term, randomized, controlled trial, J Am Soc Nephrol., 16, 2119, 10.1681/ASN.2005010001 · DOI
  97. Doherty, 1991, Pentoxifylline suppression of tumor necrosis factor gene transcription, Surgery., 110, 192
  98. Voisin, 1998, Cytokine modulation by PX differently affects specific acute phase proteins during sepsis in rats, Am J Physiol., 275, R1412, 10.1152/ajpregu.1998.275.5.R1412 · DOI
  99. Strutz, 2000, Effects of pentoxifylline, pentifylline and gamma-interferon on proliferation, differentiation, and matrix synthesis of human renal fibroblasts, Nephrol Dial Transplant., 15, 1535, 10.1093/ndt/15.10.1535 · DOI
  100. The anti-inflammatory effects of the phosphodiesterase inhibitor pentoxifylline in the rat33140 Abdel-SalamOM BaiuomyAR El-ShenawySM ArbidMS 10.1016/S1043-6618(03)00002-112644391Pharmacol Res.472003 · DOI
  101. Dávila-Esqueda, 2004, Pentoxifylline diminishes the oxidative damage to renal tissue induced by streptozotocin in the rat, Exp Diabesity Res., 5, 245, 10.1080/154386090897974 · DOI
  102. Navarro-González, 2008, The role of inflammatory cytokines in diabetic nephropathy, J Am Soc Nephrol., 19, 433, 10.1681/ASN.2007091048 · DOI
  103. Navarro, 1999, Urinary protein excretion and serum tumor necrosis factor in diabetic patients with advanced renal failure: effects of pentoxifylline administration, Am J Kidney Dis., 33, 458, 10.1016/S0272-6386(99)70182-4 · DOI
  104. Rodriguez-Morán, 2006, Effects of pentoxifylline on the urinary protein excretion profile of type 2 diabetic patients with microproteinuria: a double-blind, placebo-controlled randomized trial, Clin Nephrol., 66, 3, 10.5414/CNP66003 · DOI
  105. Goicoechea, 2012, Effects of pentoxifylline on inflammatory parameters in chronic kidney disease patients: a randomized trial, J Nephrol., 25, 969, 10.5301/jn.5000077 · DOI
  106. Lin, 2008, Effect of pentoxifylline in addition to losartan on proteinuria and GFR in CKD: a 12-month randomized trial, Am J Kidney Dis., 52, 464, 10.1053/j.ajkd.2008.05.012 · DOI
  107. Navarro-González, 2015, Effect of pentoxifylline on renal function and urinary albumin excretion in patients with diabetic kidney disease: the PREDIAN trial, J Am Soc Nephrol., 26, 220, 10.1681/ASN.2014010012 · DOI
  108. McCormick, 2008, The effect of pentoxifylline on proteinuria in diabetic kidney disease: a meta-analysis, Am J Kidney Dis., 52, 454, 10.1053/j.ajkd.2008.01.025 · DOI
  109. Tian, 2015, Efficacy and safety of combining pentoxifylline with angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker in diabetic nephropathy: a meta-analysis, Int Urol Nephrol., 47, 815, 10.1007/s11255-015-0968-2 · DOI
  110. Zhu, 2014, miR-20b suppresses Th17 differentiation and the pathogenesis of experimental autoimmune encephalomyelitis by targeting RORgammat and STAT3, J. Immunol., 192, 5599, 10.4049/jimmunol.1303488 · DOI
  111. Qu, 2016, MiR-30a inhibits Th17 differentiation and demyelination of EAE mice by targeting the IL-21R, Brain Behav Immun., 57, 193, 10.1016/j.bbi.2016.03.016 · DOI
  112. Li, 2017, MIR-146a modulates autoreactive Th17 cell differentiation and regulates organ-specific autoimmunity, J Clin Investig., 127, 3702, 10.1172/JCI94012 · DOI · Paper page
  113. Naghavian, 2015, miR-141 and miR-200a, revelation of new possible players in modulation of Th17/treg differentiation and pathogenesis of multiple sclerosis, PLoS ONE., 10, e0124555, 10.1371/journal.pone.0124555 · DOI
  114. Lin, 2015, MicroRNA-155 deficiency promotes nephrin acetylation and attenuates renal damage in hyperglycemia-induced nephropathy, Inflammation., 38, 546, 10.1007/s10753-014-9961-7 · DOI
  115. Krebs, 2013, MicroRNA-155 drives T H 17 immune response and tissue injury in experimental crescentic GN, J Am Soc Nephrol., 24, 1955, 10.1681/ASN.2013020130 · DOI
  116. Mease, 2018, Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study, Ann Rheum Dis., 77, 890, 10.1136/annrheumdis-2017-212687 · DOI
  117. Sbidian, 2017, Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis, Cochrane Database Syst Rev., 12, CD011535, 10.1002/14651858.CD011535.pub2 · DOI
  118. Lavoz, 2020, Could IL-17A be a novel therapeutic target in diabetic nephropathy?, J Clin Med, 9, 272, 10.3390/jcm9010272 · DOI

Metadata

Authors
Donate-Correa, J., Ferri, C. M., Sánchez-Quintana, F., Pérez-Castro, A., González-Luis, A., Martín-Núñez, E., Mora-Fernández, C., & Navarro-González, J. F.
Affiliations
  • Universidad de La Laguna (ES)
  • Hospital Universitario Nuestra Señora de Candelaria (ES)
ORCID
Ferri, Carla M.
Venue
Frontiers in Medicine
Publisher
Frontiers Media SA
Published
2021-01-22
Volume
7
Pages
628289-628289
ISSN
2296-858X (ISSN-L)
DOI
10.3389/fmed.2020.628289
PMC
PMC7862763
OpenAlex
W3124235172
Cited by
140
References
122
Citations by year
2026: 22 · 2025: 33 · 2024: 29 · 2023: 23 · 2022: 23 · 2021: 9
FWCI
3.48
Type
journal article
Language
en
Open access
Licence
Locations
  • Frontiers in Medicine (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Sociedad Española de Nefrología (RD16/0009)
  • Instituto de Salud Carlos III (PI16/02057, PI16/, RD16/0009, ISCIII‐RETIC REDinREN RD16/0009, PI15/00298, PI16/00024, PI07/0870)
Topics
  • Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Advanced Glycation End Products research
  • Health Sciences › Medicine › Nephrology › Dialysis and Renal Disease Management
Keywords
diabetic nephropathy, inflammatory cytokines, inflammation, pathogenesis, anti-inflammatory therapy, end-stage renal disease, cardiovascular risk, hyperglycemia, blood pressure, diabetes mellitus

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Inflammatory Cytokines in Diabetic Kidney Disease: Pathophysiologic and Therapeutic Implications. https://app.cochat.ai/papers/10.3389/fmed.2020.628289
The paper
Donate-Correa, J., Ferri, C. M., Sánchez-Quintana, F., Pérez-Castro, A., González-Luis, A., Martín-Núñez, E., Mora-Fernández, C., & Navarro-González, J. F. (2021). Inflammatory Cytokines in Diabetic Kidney Disease: Pathophysiologic and Therapeutic Implications. Frontiers in Medicine. https://doi.org/10.3389/fmed.2020.628289